Uncategorized
June 12, 2025 / January 12, 2026 by SFA Team
Tempe, AZ – June 12, 2025 – Nectero Therapeutics, a clinical-stage biotechnology company developing therapies for aneurysmal disease, announced today that the American Medical Association’s CPT Editorial Panel has approved two Category III CPT codes applicable to the Nectero EAST® System procedure via a percutaneous or open approach. This designation represents a key milestone toward […]
Read more »
September 24, 2024 / January 12, 2026 by SFA Team
TEMPE, Ariz., Sept. 24, 2024 (GLOBE NEWSWIRE) — Nectero Therapeutics, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, announced today that it received a 2024 AZBio™ Fast Lane Award from the Arizona Bioindustry Association (AZBio). Each year a select group of Arizona-based life science companies are recognized for the progress they are making […]
April 11, 2024 / January 12, 2026 by SFA Team
The proceeds will support the execution of the Phase II/III trial and potential NDA submission for the Nectero EAST System, a Breakthrough Therapy for small to medium-sized AAA. TEMPE, Ariz.–(BUSINESS WIRE)–Nectero Therapeutics, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced the closing of its $96 million Series D financing round. Financing […]
January 18, 2024 / January 12, 2026 by SFA Team
Trial to randomize 400 subjects at multiple sites, primarily in the U.S., to evaluate safety and efficacy of the investigational Nectero EAST System for treatment of infrarenal AAA, maximum diameter 3.5-5.0cm TEMPE, Ariz.–(BUSINESS WIRE)–Nectero Therapeutics, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease and improve patients’ lives, today announced initiation of a […]
November 1, 2023 / January 12, 2026 by necteromedical
TEMPE, Ariz.–(BUSINESS WIRE)–Nectero Therapeutics, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System to treat patients with infrarenal AAAs, maximum diameter 3.5 – 5.0cm. Nectero Therapeutics is initiating […]
August 24, 2023 / January 12, 2026 by necteromedical
TEMPE, Ariz.–(BUSINESS WIRE)–Nectero Therapeutics, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System to treat patients with infrarenal AAAs, maximum diameter 3.5 – 5.0cm. Nectero Therapeutics is initiating […]
July 24, 2023 / January 12, 2026 by necteromedical
Nectero Therapeutics, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease and improve patients’ lives, today announced that the U.S. Food and Drug Administration (FDA) granted Investigational New Drug (IND) clearance for the company to initiate a prospective, multi-center, randomized clinical trial (the stAAAble Study) to evaluate the safety and efficacy of the […]
September 10, 2021 / January 12, 2026 by necteromedical
Proceeds from new investors will fund in vivo and clinical development of innovative platform for aneurysmal disease, including Abdominal Aortic Aneurysms (AAA) TEMPE, Ariz.–(BUSINESS WIRE)–Nectero Therapeutics Inc. today announced the closing of its $19.5 million Series C financing round, led by new investor Boston Scientific Corporation, a leading global medical device manufacturer. Proceeds will support the company’s in […]